Fortis may be out of F&O if results delayed

The National Stock Exchange of India on Thursday said it will exclude Fortis Healthcare from the derivatives segment if the company fails to submit its financial results for the September and December quarter by March 1, reports Our Bureau.

So far, Fortis Healthcare has failed to submit its quarterly financial results for the September and December quarter, said NSE. Fortis has intimated to exchanges that its board will consider results for the two quarters in meeting on February 28.

  • Related Posts

    Glenmark Pharma’s US arm launches Latanoprost’s bioequivalent solution

    Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution. The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of…

    HC denies bail to pharma company owner for manufacturing spurious drugs

    Shimla:  The Himachal Pradesh high court on Monday declined bail to the owner of pharmaceutical company M/s Glenmars Healthcare in the Baddi area of Solan district, from where a huge…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Bharat Bio successfully completes Phase III trials of new oral cholera vaccine Hillchol

    Bharat Bio successfully completes Phase III trials of new oral cholera vaccine Hillchol

    55 drugs manufactured in Himachal found not of standard quality

    55 drugs manufactured in Himachal found not of standard quality

    42 cos banned over supply of substandard drugs

    42 cos banned over supply of substandard drugs

    Gland Pharma Q4 results: Profit dips 3% YoY to ₹187 crore; 1800% dividend announced

    Gland Pharma Q4 results: Profit dips 3% YoY to ₹187 crore; 1800% dividend announced